Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Maria Teresa Voso; Pasquale Niscola; Alfonso Piciocchi; Luana Fianchi; Luca Maurillo; Pellegrino Musto; Livio Pagano; Giovanna Mansueto; Giovanna Rosaria Mansueto; Marianna Criscuolo; Maria Antonietta Aloe-Spiriti; Francesco Buccisano; Adriano Venditti; Andrea Tendas; Anna Lina Piccioni; Gina Zini Tanzi; Roberto Latagliata; Nunzio Filardi; Antonia Natalina Filardi; Alberto Fragasso; Susanna Fenu; Massimo Breccia; Marco Breccia

doi:10.1111/ejh.12595

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Maria Teresa Voso
, Pasquale Niscola
, Alfonso Piciocchi
, Luana Fianchi
, Luca Maurillo
, Pellegrino Musto
, Livio Pagano
, Giovanna Mansueto
, Giovanna Rosaria Mansueto
, Marianna Criscuolo
, Maria Antonietta Aloe-Spiriti
, Francesco Buccisano
, Adriano Venditti
, Andrea Tendas
, Anna Lina Piccioni
, Gina Zini Tanzi
, Roberto Latagliata
, Nunzio Filardi
, Antonia Natalina Filardi
, Alberto Fragasso

Susanna Fenu, Massimo Breccia, Marco Breccia

University of Rome Tor Vergata
ASL Roma 2
University of Rome La Sapienza
IRCCS Centro di riferimento oncologico della Basilicata - Rionero in Vulture (PZ)
Sant'Andrea Hospital
Ospedale San Carlo, Potenza
Ospedale Madonna delle Grazie
Hospital San Giovanni Addolorata

Risultato della ricerca: Contributo in rivista › Articolo

23 Citazioni (Scopus)

Abstract

Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Rivista	European Journal of Haematology
Volume	2015
DOI	https://doi.org/10.1111/ejh.12595
Stato di pubblicazione	Pubblicato - 2015

Keywords

AML
MDS
azacitidine

Accesso al documento

10.1111/ejh.12595

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Voso, M. T., Niscola, P., Piciocchi, A., Fianchi, L., Maurillo, L., Musto, P., Pagano, L., Mansueto, G., Mansueto, G. R., Criscuolo, M., Aloe-Spiriti, M. A., Buccisano, F., Venditti, A., Tendas, A., Piccioni, A. L., Zini Tanzi, G., Latagliata, R., Filardi, N., Filardi, A. N., ... Breccia, M. (2015). Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. European Journal of Haematology, 2015, N/A-N/A. https://doi.org/10.1111/ejh.12595

@article{acf26a75985647d69422bd74021b4bd0,

title = "Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia",

abstract = "Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.",

keywords = "AML, MDS, azacitidine, AML, MDS, azacitidine",

author = "Voso, \{Maria Teresa\} and Pasquale Niscola and Alfonso Piciocchi and Luana Fianchi and Luca Maurillo and Pellegrino Musto and Livio Pagano and Giovanna Mansueto and Mansueto, \{Giovanna Rosaria\} and Marianna Criscuolo and Aloe-Spiriti, \{Maria Antonietta\} and Francesco Buccisano and Adriano Venditti and Andrea Tendas and Piccioni, \{Anna Lina\} and \{Zini Tanzi\}, Gina and Roberto Latagliata and Nunzio Filardi and Filardi, \{Antonia Natalina\} and Alberto Fragasso and Susanna Fenu and Massimo Breccia and Marco Breccia",

year = "2015",

doi = "10.1111/ejh.12595",

language = "English",

volume = "2015",

pages = "N/A--N/A",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

}

Voso, MT, Niscola, P, Piciocchi, A, Fianchi, L, Maurillo, L, Musto, P, Pagano, L, Mansueto, G, Mansueto, GR, Criscuolo, M, Aloe-Spiriti, MA, Buccisano, F, Venditti, A, Tendas, A, Piccioni, AL, Zini Tanzi, G, Latagliata, R, Filardi, N, Filardi, AN, Fragasso, A, Fenu, S, Breccia, M & Breccia, M 2015, 'Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia', European Journal of Haematology, vol. 2015, pagg. N/A-N/A. https://doi.org/10.1111/ejh.12595

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. / Voso, Maria Teresa; Niscola, Pasquale; Piciocchi, Alfonso et al.
In: European Journal of Haematology, Vol. 2015, 2015, pag. N/A-N/A.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

AU - Voso, Maria Teresa

AU - Niscola, Pasquale

AU - Piciocchi, Alfonso

AU - Fianchi, Luana

AU - Maurillo, Luca

AU - Musto, Pellegrino

AU - Pagano, Livio

AU - Mansueto, Giovanna

AU - Mansueto, Giovanna Rosaria

AU - Criscuolo, Marianna

AU - Aloe-Spiriti, Maria Antonietta

AU - Buccisano, Francesco

AU - Venditti, Adriano

AU - Tendas, Andrea

AU - Piccioni, Anna Lina

AU - Zini Tanzi, Gina

AU - Latagliata, Roberto

AU - Filardi, Nunzio

AU - Filardi, Antonia Natalina

AU - Fragasso, Alberto

AU - Fenu, Susanna

AU - Breccia, Massimo

AU - Breccia, Marco

PY - 2015

Y1 - 2015

N2 - Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

AB - Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

KW - AML

KW - MDS

KW - azacitidine

KW - AML

KW - MDS

KW - azacitidine

UR - http://hdl.handle.net/10807/71738

U2 - 10.1111/ejh.12595

DO - 10.1111/ejh.12595

M3 - Article

SN - 0902-4441

VL - 2015

SP - N/A-N/A

JO - European Journal of Haematology

JF - European Journal of Haematology

ER -

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo